Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Baxter To End Watson Ferrlecit Co-Promotion Under FTC Consent Order

Executive Summary

A Federal Trade Commission consent order will require Baxter to end its co-marketing agreement with Watson for Ferrlecit in connection with Baxter's acquisition of Wyeth's generic injectable drug business

You may also be interested in...

Baxter Adding $200 Mil. In Critical Care Rx Sales Via ESI Lederle Deal

Baxter is adding about $200 mil. in annual sales to its anesthesia/critical care line via the acquisition of ESI Lederle from Wyeth

Watson/Baxter Ferrlecit

Baxter will contribute 80 sales reps to help detail Watson's anemia drug Ferrlecit under a co-promotion agreement-in-principle announced March 14. Baxter's force will double the size of the Ferrlecit sales team; Watson employs 75 Ferrlecit reps. The deal gives Baxter the opportunity to supplement its renal care business with traditional pharmaceuticals. FDA approved the injectable iron product in 1999. Sales were about $140 mil. in 2001...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts